231 related articles for article (PubMed ID: 29569717)
1. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis.
Uddin S; Jehan Z; Ahmed M; Alyan A; Al-Dayel F; Hussain A; Bavi P; Al-Kuraya KS
Mol Med; 2011; 17(7-8):635-45. PubMed ID: 21442130
[TBL] [Abstract][Full Text] [Related]
3. Fatty Acid Inhibition Sensitizes Androgen-Dependent and -Independent Prostate Cancer to Radiotherapy via FASN/NF-κB Pathway.
Chuang HY; Lee YP; Lin WC; Lin YH; Hwang JJ
Sci Rep; 2019 Sep; 9(1):13284. PubMed ID: 31527721
[TBL] [Abstract][Full Text] [Related]
4. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype.
Kant S; Kumar A; Singh SM
Biochim Biophys Acta; 2014 Jan; 1840(1):294-302. PubMed ID: 24060750
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
[TBL] [Abstract][Full Text] [Related]
7. FASN inhibition sensitizes metastatic OSCC cells to cisplatin and paclitaxel by downregulating cyclin B1.
Almeida LY; Moreira FDS; Santos GASD; Cuadra Zelaya FJM; Ortiz CA; Agostini M; Mariano FS; Bastos DC; Daher URN; Kowalski LP; Coletta RD; Graner E
Oral Dis; 2023 Mar; 29(2):649-660. PubMed ID: 34510641
[TBL] [Abstract][Full Text] [Related]
8. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.
Yang CS; Matsuura K; Huang NJ; Robeson AC; Huang B; Zhang L; Kornbluth S
Oncogene; 2015 Jun; 34(25):3264-72. PubMed ID: 25151963
[TBL] [Abstract][Full Text] [Related]
10. Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism.
Shueng PW; Chan HW; Lin WC; Kuo DY; Chuang HY
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742944
[TBL] [Abstract][Full Text] [Related]
11. A FASN-TGF-β1-FASN regulatory loop contributes to high EMT/metastatic potential of cisplatin-resistant non-small cell lung cancer.
Yang L; Zhang F; Wang X; Tsai Y; Chuang KH; Keng PC; Lee SO; Chen Y
Oncotarget; 2016 Aug; 7(34):55543-55554. PubMed ID: 27765901
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer.
Bauerschlag DO; Maass N; Leonhardt P; Verburg FA; Pecks U; Zeppernick F; Morgenroth A; Mottaghy FM; Tolba R; Meinhold-Heerlein I; Bräutigam K
J Transl Med; 2015 May; 13():146. PubMed ID: 25947066
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.
Cioccoloni G; Aquino A; Notarnicola M; Caruso MG; Bonmassar E; Zonfrillo M; Caporali S; Faraoni I; Villivà C; Fuggetta MP; Franzese O
J Chemother; 2020 Feb; 32(1):30-40. PubMed ID: 31775585
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
15. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas.
Agostini M; Almeida LY; Bastos DC; Ortega RM; Moreira FS; Seguin F; Zecchin KG; Raposo HF; Oliveira HC; Amoêdo ND; Salo T; Coletta RD; Graner E
Mol Cancer Ther; 2014 Mar; 13(3):585-95. PubMed ID: 24362464
[TBL] [Abstract][Full Text] [Related]
16. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy.
Schcolnik-Cabrera A; Chávez-Blanco A; Domínguez-Gómez G; Taja-Chayeb L; Morales-Barcenas R; Trejo-Becerril C; Perez-Cardenas E; Gonzalez-Fierro A; Dueñas-González A
Expert Opin Investig Drugs; 2018 May; 27(5):475-489. PubMed ID: 29723075
[TBL] [Abstract][Full Text] [Related]
17. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer.
Sadowski MC; Pouwer RH; Gunter JH; Lubik AA; Quinn RJ; Nelson CC
Oncotarget; 2014 Oct; 5(19):9362-81. PubMed ID: 25313139
[TBL] [Abstract][Full Text] [Related]
18. Carbon monoxide sensitizes cisplatin-resistant ovarian cancer cell lines toward cisplatin via attenuation of levels of glutathione and nuclear metallothionein.
Kawahara B; Ramadoss S; Chaudhuri G; Janzen C; Sen S; Mascharak PK
J Inorg Biochem; 2019 Feb; 191():29-39. PubMed ID: 30458366
[TBL] [Abstract][Full Text] [Related]
19. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression.
Heuer TS; Ventura R; Mordec K; Lai J; Fridlib M; Buckley D; Kemble G
EBioMedicine; 2017 Feb; 16():51-62. PubMed ID: 28159572
[TBL] [Abstract][Full Text] [Related]
20. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
